Brought to you by 
Retrophin sells products to former CEO Martin Shkreli’s newco Turing Pharma
23 Nov 2021
Executive Summary
Amid management and board shake-ups, including the replacement of its CEO Martin Shkreli, Retrophin Inc. (pediatric orphan and other diseases) scaled down its portfolio and sold Turing Pharmaceuticals LLC three non-core products for $3mm. Martin Shkreli, who also resigned from Retrophin’s board, founded Turing Pharmaceuticals to take over these assets.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Retrophin sells products to former CEO Martin Shkreli’s newco Turing Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice